Analysts Issue Forecasts for SGMT Q2 Earnings

Key Points

• HC Wainwright projects Sagimet Biosciences (SGMT) will report Q2 2025 earnings of ($0.55) per share, maintaining a "Buy" rating with a target price of $29.00.
• The company reported its last quarterly earnings of (0.56) EPS, exceeding analysts' expectations by $0.23.
• As of now, six investment analysts have rated Sagimet Biosciences as a buy, with a consensus target price of $26.33.

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Sagimet Biosciences in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of ($0.55) per share for the quarter. HC Wainwright has a "Buy" rating and a $29.00 price objective on the stock. The consensus estimate for Sagimet Biosciences' current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Sagimet Biosciences' Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.24) EPS, FY2026 earnings at ($2.78) EPS, FY2027 earnings at ($3.13) EPS, FY2028 earnings at ($4.02) EPS and FY2029 earnings at ($2.56) EPS.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.20.

A number of other equities analysts also recently commented on the company. Jones Trading upped their target price on Sagimet Biosciences from $15.00 to $27.00 and gave the company a "buy" rating in a report on Friday, June 6th. Wedbush began coverage on Sagimet Biosciences in a research note on Monday. They issued an "outperform" rating and a $28.00 target price on the stock. Finally, Canaccord Genuity Group started coverage on shares of Sagimet Biosciences in a report on Thursday, July 24th. They set a "buy" rating and a $28.00 price objective for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $26.57.

Sagimet Biosciences Stock Performance

NASDAQ:SGMT traded down $0.67 during mid-day trading on Monday, reaching $8.91. The stock had a trading volume of 234,691 shares, compared to its average volume of 1,099,864. Sagimet Biosciences has a one year low of $1.73 and a one year high of $11.41. The firm has a 50 day moving average price of $8.52 and a two-hundred day moving average price of $5.22. The stock has a market capitalization of $273.27 million, a P/E ratio of -5.05 and a beta of 3.37.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Millennium Management LLC raised its holdings in shares of Sagimet Biosciences by 257.1% during the fourth quarter. Millennium Management LLC now owns 693,247 shares of the company's stock valued at $3,120,000 after acquiring an additional 499,094 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Sagimet Biosciences by 0.6% during the 2nd quarter. Geode Capital Management LLC now owns 265,324 shares of the company's stock worth $2,023,000 after purchasing an additional 1,600 shares during the period. Bridgeway Capital Management LLC boosted its position in shares of Sagimet Biosciences by 62.0% during the fourth quarter. Bridgeway Capital Management LLC now owns 224,100 shares of the company's stock worth $1,008,000 after buying an additional 85,800 shares during the period. Jump Financial LLC purchased a new position in shares of Sagimet Biosciences during the second quarter worth $1,130,000. Finally, 683 Capital Management LLC purchased a new position in shares of Sagimet Biosciences during the fourth quarter worth $622,000. 87.86% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Sagimet Biosciences

In other news, CEO David Happel sold 65,478 shares of the business's stock in a transaction on Monday, July 21st. The stock was sold at an average price of $9.13, for a total value of $597,814.14. Following the completion of the transaction, the chief executive officer directly owned 689,722 shares of the company's stock, valued at approximately $6,297,161.86. The trade was a 8.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eduardo Bruno Martins sold 8,277 shares of the stock in a transaction on Monday, July 21st. The shares were sold at an average price of $9.13, for a total value of $75,569.01. Following the sale, the insider owned 106,936 shares of the company's stock, valued at approximately $976,325.68. This represents a 7.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 84,535 shares of company stock worth $771,805 in the last quarter. 14.70% of the stock is owned by company insiders.

Sagimet Biosciences Company Profile

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.